Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-HF2: Ferric Carboxymaltose in Heart Failure
NCT03036462Phase 4Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Mar 2017
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial in iron deficiency anemia (IDA) comparing Verum group (FCM) with Placebo group (NaCL) (2 arms). Primary endpoints: Time-to-first event of cardiovascular death or heart failure hospitalisation up to 36 months, Rate of total (first and recurrent) events of hospitalisations for heart failure up to 36 months and 1 more. Started Mar 2017; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03036462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036462.